| Literature DB >> 30046488 |
Katherin Steffy1, G Shanthi1, Anson S Maroky2, S Selvakumar3.
Abstract
Nanobiotechnology has been emerged as an efficient technology for the development of antimicrobial nanoparticles through an eco-friendly approach. In this study, green synthesized phytonanocomposite of ZnO from Strychnos nux-vomica leaf aqueous extract was characterized by X-ray diffraction analysis (XRD), UV-visible-spectroscopy, Photoluminescence spectroscopy (PL), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), High-resolution Transmission Electron Microscopy (HR-TEM), and Energy dispersive X-ray analysis (EDX). Antibacterial activity was investigated against multidrug-resistant bacteria (MDR) isolated from diabetic foot ulcers (DFUs), such as MDR-methicillin resistant Staphylococcus aureus (MRSA), MDR-Escherichia coli, MDR-Pseudomonas aeruginosa, MDR-Acinetobacter baumannii, as well as against standard bacterial strains, S. aureus ATCC 29213, E. coli ATCC 25922, P. aeruginosa ATCC 27853, and E. faecalis ATCC 29212 through disc diffusion assays on Muller Hinton Agar. The characterization studies revealed a size-controlled synthesis of quasi-spherical hexagonal wurtzite structured ZnO phytonanocomposite with an average size of 15.52 nm. Additionally, remarkable bactericidal activities against MDR clinical as well as ATCC bacterial strains were exhibited, with a maximum zone of inhibition of 22.33 ± 1.53 mm (against S. aureus ATCC 29213) and 22.33 ± 1.16 mm (MDR-MRSA) at a concentration of 400 µg/mL. This study thus established the possibility of developing antimicrobial ZnO nanocomposite of Strychnos nux-vomica leaf extract to combat developing drug resistance currently being experienced in health care facilities.Entities:
Keywords: Antibacterial activity; Multidrug resistance (MDR); Strychnos nux-vomica; ZnO phytonanocomposite
Year: 2017 PMID: 30046488 PMCID: PMC6057447 DOI: 10.1016/j.jare.2017.11.001
Source DB: PubMed Journal: J Adv Res ISSN: 2090-1224 Impact factor: 10.479
Fig. 1XRD pattern of biosynthesized S. nux-vomica–ZnO nanocomposite.
Fig. 2UV–visible absorbance spectra of (a) biosynthesized S. nux-vomica–ZnO nanocomposite (b) bare ZnO nanoparticles at room temperature.
Fig. 3Photoluminescence of (a) S. nux-vomica–ZnO nanocomposite in 40 mL (b) bare ZnO nanoparticles at room temperature.
Fig. 4FTIR spectra of (a) S. nux-vomica leaf aqueous extract (b) biosynthesized S. nux-vomica–ZnO nanocomposite in 40 mL (c) bare ZnO nanoparticles.
Fig. 5XPS of biosynthesized S. nux-vomica–ZnO nanocomposite in 40 mL (a) wide range, (b) Zn, (c) O.
Fig. 6TEM image of (a) annealed biosynthesized S. nux-vomica–ZnO nanocomposite in 40 mL inset picture of higher magnification, (b) gaussian distribution of particle size corresponding to TEM images, (c) selected area electron diffraction (SAED) pattern, (d) HR-TEM image.
Fig. 7EDX spectrum of biosynthesized S. nux-vomica–ZnO nanocomposite in 40 mL.
Mean zone of inhibition (mm)a by disc diffusionb assay.
| Name | Bare ZnO nano (400 µg/mL) | Control | Antibiotic | |||
|---|---|---|---|---|---|---|
| 7.33 ± 1.53 | 6.33 ± 0.58 | 16.00 ± 1.00 | 22.33 ± 1.53 | – | 18.33 ± 0.58 | |
| 8.00 ± 1.00 | 6.33 ± 0.58 | 9.67 ± 0.58 | 16.00 ± 1.00 | – | 12.67 ± 0.58 | |
| 8.00 ± 0.00 | 7.00 ± 1.00 | 11.00 ± 1.00 | 12.33 ± 0.58 | – | 18.00 ± 1.00 | |
| 7.00 ± 1.00 | 9.33 ± 0.58 | 11.33 ± 0.58 | 16.00 ± 1.00 | – | 18.33 ± 0.58 | |
| MDR–MRSA | 7.33 ± 1.53 | 7.00 ± 0.00 | 20.00 ± 1.00 | 22.33 ± 1.16 | – | 18.33 ± 0.58 |
| MDR– | 7.00 ± 1.00 | 6.33 ± 0.58 | 10.33 ± 0.58 | 13.33 ± 1.53 | – | 12.67 ± 0.58 |
| MDR– | 7.67 ± 0.58 | 7.00 ± 1.00 | 8.00 ± 1.00 | 13.00 ± 1.00 | – | 11.00 ± 1.00 |
| MDR– | 7.00 ± 1.00 | 7.00 ± 1.00 | 12.67 ± 0.58 | 16.00 ± 1.00 | – | 12.67 ± 0.58 |
< .05 in comparison with S. nux-vomica Crude. P < .05 was considered as statistically significant.
Diameter zone of inhibition (mm) including the disc diameter of 6 mm.
Mean ± SD of three independent experiments.
S. nux-vomica crude extract.
Negative control 20% DMSO.
Antibiotic positive control Vancomycin 30 µg/mL for Gram-positive and Colistin 10 µg/mL for Gram-negative bacteria.
Non significant.
P < .001.
P < .01.